TY - JOUR
T1 - Psoriasis exacerbation after COVID-19 vaccines
T2 - A brief report of the reported cases
AU - El-Qushayri, Amr Ehab
AU - Nardone, Beatrice
N1 - Publisher Copyright:
© 2022 Wiley Periodicals LLC.
PY - 2022/12
Y1 - 2022/12
N2 - Despite the significant reduction of both morbidity and mortality after the introduction of many vaccines against COVID-19, recent reports indicated a worsening skin conditions in particular patients with psoriasis. We extracted the data of 51 patients from 19 papers. The mean age was 56.9 (SD = 16.2) years, with a male prevalence 45%. Of the 51 cases, vaccine types at which psoriasis flare occurred were as the following: Pfizer vaccine (30), AstraZeneca (9), Moderna (8), Coronavac (2) Covishield (1), and Covaxin (1). Exacerbation was common in the second dose of Pfizer, AstraZeneca, Moderna, and Covishield vaccines. Moreover, the onset of psoriasis exacerbation was shorter after the second dose of Pfizer (mean = 12.8 [SD = 15.2]) and AstraZeneca (mean = 7.4 [SD = 3.6]) rather than the first dose of both vaccines, respectively (mean = 19.2 [SD = 21.3]) and (mean = 18.5 [SD = 10.7]).
AB - Despite the significant reduction of both morbidity and mortality after the introduction of many vaccines against COVID-19, recent reports indicated a worsening skin conditions in particular patients with psoriasis. We extracted the data of 51 patients from 19 papers. The mean age was 56.9 (SD = 16.2) years, with a male prevalence 45%. Of the 51 cases, vaccine types at which psoriasis flare occurred were as the following: Pfizer vaccine (30), AstraZeneca (9), Moderna (8), Coronavac (2) Covishield (1), and Covaxin (1). Exacerbation was common in the second dose of Pfizer, AstraZeneca, Moderna, and Covishield vaccines. Moreover, the onset of psoriasis exacerbation was shorter after the second dose of Pfizer (mean = 12.8 [SD = 15.2]) and AstraZeneca (mean = 7.4 [SD = 3.6]) rather than the first dose of both vaccines, respectively (mean = 19.2 [SD = 21.3]) and (mean = 18.5 [SD = 10.7]).
KW - COVID-19 vaccine
KW - COVID-19 vaccines
KW - exacerbation
KW - flare
KW - psoriasis
UR - http://www.scopus.com/inward/record.url?scp=85139826105&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139826105&partnerID=8YFLogxK
U2 - 10.1111/dth.15900
DO - 10.1111/dth.15900
M3 - Article
C2 - 36200490
AN - SCOPUS:85139826105
SN - 1396-0296
VL - 35
JO - Dermatologic Therapy
JF - Dermatologic Therapy
IS - 12
M1 - e15900
ER -
